非肝硬化慢性乙型肝炎患者中每日阿司匹林治疗与肝细胞癌风险的关联:基于代谢危险因素负担的分析
该研究利用韩国国民健康保险服务数据库,纳入282,611例非肝硬化慢性乙型肝炎成人,按代谢危险因素负担分为低危组(≤2个)和高危组(≥3个),通过倾向性评分匹配比较阿司匹林使用者与非使用者的肝细胞癌、肝病相关死亡及大出血风险。中位随访7.4年,结果显示在高代谢风险组中,阿司匹林使用与肝细胞癌风险和肝病相关死亡风险降低相关,且未增加大出血风险;而在低代谢风险组中,阿司匹林使用与肝细胞癌风险无显著关联,但与大出血风险升高相关。
要点
- 高代谢风险组(≥3个危险因素)中,阿司匹林使用与肝细胞癌风险降低相关(aSHR 0.72;95% CI 0.57-0.91)。
- 高代谢风险组中,阿司匹林使用与肝病相关死亡风险降低相关(aSHR 0.69;95% CI 0.50-0.96),且未增加大出血风险(aSHR 1.02;95% CI 0.79-1.32)。
- 低代谢风险组(≤2个危险因素)中,阿司匹林使用与肝细胞癌风险无显著关联(aSHR 0.93;95% CI 0.84-1.03),但与大出血风险升高相关(aSHR 1.22;95% CI 1.08-1.39)。
核心结论
- 在代谢危险因素负担较高的非肝硬化慢性乙型肝炎患者中,阿司匹林治疗与肝细胞癌风险和肝病相关死亡风险降低相关,且未增加大出血风险。
研究设计与样本
- 基于韩国国民健康保险服务数据库的倾向性评分匹配队列研究,纳入282,611例非肝硬化慢性乙型肝炎成人,按代谢危险因素负担分为低危组(≤2个)和高危组(≥3个),比较阿司匹林使用者与非使用者。
主要发现
- 中位随访7.4年,代谢危险因素负担与结局呈正相关(所有趋势P<0.001)。
- 低代谢风险组(13,104对匹配)中,阿司匹林使用与肝细胞癌风险无显著关联(aSHR 0.93;95% CI 0.84-1.03),与大出血风险升高相关(aSHR 1.22;95% CI 1.08-1.39)。
- 高代谢风险组(2,984对匹配)中,阿司匹林使用与肝细胞癌风险降低相关(aSHR 0.72;95% CI 0.57-0.91),与肝病相关死亡风险降低相关(aSHR 0.69;95% CI 0.50-0.96),大出血风险未增加(aSHR 1.02;95% CI 0.79-1.32)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several studies have demonstrated chemopreventive effects of aspirin against hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). AIMS: To investigate the associations of aspirin use with risks of HCC, liver-related mortality, and major bleeding according to metabolic risk factor burden among non-cirrhotic patients with CHB METHODS: Using the Korean National Health Insurance Service database, we identified 282,611 non-cirrhotic adults with CHB. Data on obesity, diabetes, high blood pressure, and hypercholesterolemia were collected. Subjects were stratified into lower and higher metabolic risk groups (≤2 and ≥3 risk factors, respectively). Propensity score-matched cohorts of aspirin users and non-users were generated. Risks of HCC, liver-related death and major bleeding were analyzed. RESULTS: During the median follow-up of 7.4 years, positive associations between metabolic risk factor burden and outcomes were verified (all ptrend < 0.001). In the lower metabolic risk group (13,104 pairs), the association between aspirin use and HCC risk was not significant after multivariable adjustment (adjusted subdistribution hazard ratio [aSHR]: 0.93; 95% CI: 0.84-1.03); however, aspirin use was associated with elevated major bleeding risk (aSHR: 1.22; 95% CI: 1.08-1.39). In the higher metabolic risk group (2984 pairs), aspirin use was associated with reduced risks of HCC (aSHR: 0.72; 95% CI: 0.57-0.91) and liver-related mortality (aSHR: 0.69; 95% CI: 0.50-0.96) without an increase in risk of major bleeding (aSHR: 1.02; 95% CI: 0.79-1.32). CONCLUSIONS: Aspirin therapy was associated with reduced risks of HCC and liver-related death without excess risk of major bleeding, in non-cirrhotic patients with CHB who had a higher metabolic risk factor burden.
引用
- Lee CH, Lee YB, Moon H, et al. Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B. Aliment Pharmacol Ther. 2023. PMID: 37461332. doi:10.1111/apt.17643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。